LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
−1.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6M | 2.0M | 11.2M | (2.9M) | 500.0K |
| Cost of Revenue | 29.8K | 8.6M | — | 10.2M | 8.6M |
| Gross Profit | 1.5M | (6.6M) | 11.2M | (13.0M) | (8.1M) |
| Operating Expenses | |||||
| R&D Expense | 10.2M | — | 7.4M | — | — |
| SG&A Expense | 3.9M | 3.8M | 5.0M | 4.9M | 4.1M |
| General & Admin Expense | 3.9M | 3.8M | 5.0M | 4.9M | 4.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (31.1K) | — | — | — | — |
| Total Operating Expenses | 14.1M | 3.8M | 12.4M | 4.9M | 4.1M |
| Cost and Expenses | 14.1M | 12.3M | 12.4M | 15.1M | 12.6M |
| Operating Income (EBIT) | (12.6M) | (10.4M) | (1.2M) | (17.9M) | (12.1M) |
| Non-Operating | |||||
| Interest Income | 717.3K | 744.1K | 1.1M | 1.4M | 572.6K |
| Interest Expense | — | — | — | — | 27.1K |
| Net Interest Income | 717.3K | 744.1K | 1.1M | 1.4M | 545.5K |
| Other Non-Op Income/Expense | 717.3K | 744.1K | 1.2M | 1.6M | 1.4M |
| Non-Operating Income (excl Interest) | (717.3K) | (744.1K) | (1.2M) | (1.6M) | (1.4M) |
| EBT (Pre-Tax Income) | (11.9M) | (9.6M) | 9.0K | (16.4M) | (10.8M) |
| Income Tax Expense | 200.00 | 200.00 | 681.00 | 755.00 | 681.00 |
| Bottom Line | |||||
| Net Income | (11.9M) | (9.6M) | 8.4K | (16.4M) | (10.8M) |
| Earnings from Cont. Ops | (11.9M) | (9.6M) | 8.4K | (16.4M) | (10.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.9M) | (9.6M) | (8.8K) | (16.6M) | (11.3M) |
| Per Share | |||||
| Basic EPS | ($1.87) | ($1.77) | $0.00 | ($3.14) | ($2.15) |
| Diluted EPS | ($1.87) | ($1.69) | ($0.00) | ($3.14) | ($2.05) |
| Revenue Per Share | $0.19 | $0.36 | $2.10 | ($0.54) | $0.10 |
| Shares | |||||
| Basic Shares Outstanding | 8.2M | 5.4M | 5.3M | 5.3M | 5.0M |
| Diluted Shares Outstanding | 8.2M | 5.7M | 5.4M | 5.3M | 5.3M |
| Profitability Metrics | |||||
| EBITDA | (11.8M) | (9.6M) | 50.1K | (16.3M) | (10.7M) |
| D&A | 58.6K | 60.8K | 41.1K | 28.7K | 9.5K |
| EBIT | (11.9M) | (9.6M) | 9.0K | (16.4M) | (10.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026